Cadence is developing a next generation read/write brain computer interface (BCI) platform technology. The company’s breakthrough hardware and software system reads neural signals directly from the cortical surface of the brain and also writes back into the brain using novel brain mapping algorithms and precisely focused and individualized electrical signals. This closed-loop neuromodulation technology is being deployed to treat drug-resistant epilepsy and other brain-related conditions. Core technology in-licensing and development partnerships are in place. Epilepsy is one of the most prevalent and debilitating neurological disorders, which manifests as sudden, unexpected seizures that can significantly limit human potential. Current pharmacological and surgical approaches to epilepsy are inadequate for many patients with the disorder. Cadence’s technology will allow people with epilepsy and other neurological conditions to reduce the severity of their conditions and in many cases return to normal lives.